EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In silico screening of cucurbitacin variants identifies 11-deoxycucurbitacin I as a candidate ligand for the NACHT domain of NLRP3

Sarmoko, Ahmad Zammi Autadan Hakim, Nisa Yulianti Suprahman, Refsya Azanti Putri, Muhammad Yogi Saputra, Tantri Liris Nareswari, Manami Toriyama

Pharmacy Reports · 30.06.2026 · 6 (2) · 125

DOI: 10.51511/pr.125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacy Reports, online erschienen am 30.06.2026. Verfasst von Sarmoko und 6 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic inflammation contributes to a wide range of diseases, driving the need for novel anti-inflammatory agents with minimal side effects. The NACHT domain of NLRP3 mediates ATP-dependent inflammasome assembly and represents a validated target for anti-inflammatory therapy. This study aimed to predict and compare the binding interactions of twenty-two cucurbitacin variants against the NACHT domain using molecular docking, following geometry optimization with Density Functional Theory (B3LYP/6-31G(d)). Docking validation reproduced the native ligand pose with an RMSD of 0.87 angstrom. Among all variants tested, 11-deoxycucurbitacin I showed the most favorable predicted binding energy (-7.38 kcal/mol), sharing several interacting residues with the native ligand RM5, including Ala227, Ala228, Pro352, Ile411, Phe575, and Met661, although its predicted affinity remained weaker than that of RM5 (-10.35 kcal/mol). These shared contacts suggest that 11-deoxycucurbitacin I may engage a similar region of the NACHT inhibitor-binding pocket as RM5. In conclusion, 11-deoxycucurbitacin I is identified as the most favorable predicted binder among the cucurbitacin variants tested toward the NACHT domain, representing a candidate warranting further experimental validation.

Zitieren

APA

Sarmoko, Hakim, A. Z. A., Suprahman, N. Y., Putri, R. A., Saputra, M. Y., Nareswari, T. L., & Toriyama, M. (2026). In silico screening of cucurbitacin variants identifies 11-deoxycucurbitacin I as a candidate ligand for the NACHT domain of NLRP3. Pharmacy Reports, 6(2), 125. https://doi.org/10.51511/pr.125

Vancouver

Sarmoko, Hakim AZA, Suprahman NY, Putri RA, Saputra MY, Nareswari TL, et al. In silico screening of cucurbitacin variants identifies 11-deoxycucurbitacin I as a candidate ligand for the NACHT domain of NLRP3. Pharmacy Reports. 2026;6(2):125. doi:10.51511/pr.125

BibTeX
@article{Sarmoko2026,
  author = {Sarmoko and Hakim, Ahmad Zammi Autadan and Suprahman, Nisa Yulianti and Putri, Refsya Azanti and Saputra, Muhammad Yogi and Nareswari, Tantri Liris and Toriyama, Manami},
  title = {In silico screening of cucurbitacin variants identifies 11-deoxycucurbitacin I as a candidate ligand for the NACHT domain of NLRP3},
  journal = {Pharmacy Reports},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {125},
  doi = {10.51511/pr.125}
}
Kostenlos starten →